Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Fung, P, Bedogni, G, Bedogni, A, Petrie, A, Porter, S, Campisi, G, Bagan, J, Fusco, V, Saia, G, Acham, S, Musto, P, Petrucci, MT, Diz, P, Colella, G, Mignogna, MD, Pentenero, M, Arduino, P, Lodi, G, Maiorana, C, Manfredi, M, Hallberg, P, Wadelius, M, Takaoka, K, Leung, YY, Bonacina, R, Schiødt, M, Lakatos, P, Taylor, ST, De Riu, G, Favini, G, Rogers, SN, Pirmohamed, M, Nicoletti, P, Fedele, S & GENVABO Consortium 2017, 'Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study' Oral Diseases, bind 23, nr. 4, s. 477-483. https://doi.org/10.1111/odi.12632

APA

Fung, P., Bedogni, G., Bedogni, A., Petrie, A., Porter, S., Campisi, G., ... GENVABO Consortium (2017). Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study. Oral Diseases, 23(4), 477-483. https://doi.org/10.1111/odi.12632

CBE

Fung P, Bedogni G, Bedogni A, Petrie A, Porter S, Campisi G, Bagan J, Fusco V, Saia G, Acham S, Musto P, Petrucci MT, Diz P, Colella G, Mignogna MD, Pentenero M, Arduino P, Lodi G, Maiorana C, Manfredi M, Hallberg P, Wadelius M, Takaoka K, Leung YY, Bonacina R, Schiødt M, Lakatos P, Taylor ST, De Riu G, Favini G, Rogers SN, Pirmohamed M, Nicoletti P, Fedele S, GENVABO Consortium. 2017. Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study. Oral Diseases. 23(4):477-483. https://doi.org/10.1111/odi.12632

MLA

Vancouver

Author

Fung, Ppl ; Bedogni, G ; Bedogni, A ; Petrie, Aviva ; Porter, S ; Campisi, G ; Bagan, J ; Fusco, V ; Saia, G ; Acham, S ; Musto, Pellegrino ; Petrucci, M T ; Diz, P ; Colella, G ; Mignogna, M D ; Pentenero, M ; Arduino, P ; Lodi, G ; Maiorana, Carlo ; Manfredi, M ; Hallberg, P ; Wadelius, M ; Takaoka, K ; Leung, Ying Ying ; Bonacina, R ; Schiødt, M ; Lakatos, P. ; Taylor, S T ; De Riu, G ; Favini, G ; Rogers, S N ; Pirmohamed, M ; Nicoletti, P ; Fedele, S ; GENVABO Consortium. / Time to onset of bisphosphonate-related osteonecrosis of the jaws : a multicentre retrospective cohort study. I: Oral Diseases. 2017 ; Bind 23, Nr. 4. s. 477-483.

Bibtex

@article{da501285c6ee44958a2741df6d46ec2a,
title = "Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study",
abstract = "OBJECTIVES: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of bisphosphonates (BP). Although the risk of ONJ increases with increasing duration of BP treatment, there are currently no reliable estimates of the ONJ time to onset (TTO). The objective of this study was to estimate the TTO and associated risk factors in BP-treated patients.SUBJECTS AND METHODS: Retrospective analysis of data from 22 secondary care centres in seven countries relevant to 349 patients who developed BP-related ONJ between 2004 and 2012.RESULTS: The median (95{\%}CI) TTO was 6.0 years in patients treated with alendronate (n = 88) and 2.2 years in those treated with zoledronate (n = 218). Multivariable Cox regression showed that dentoalveolar surgery was inversely associated, and the use of antiangiogenics directly associated, with the TTO in patients with cancer treated with zoledronate.CONCLUSIONS: The incidence of ONJ increases with the duration of BP therapy, with notable differences observed with respect to BP type and potency, route of administration and underlying disease. When data are stratified by BP type, a time of 6.0 and 2.2 years of oral alendronate and intravenous zoledronate therapy, respectively, is required for 50{\%} of patients to develop ONJ. After stratification by disease, a time of 5.3 and 2.2 years of BP therapy is required for 50{\%} of patients with osteoporosis and cancer, respectively, to develop ONJ. These findings have significant implications for the design of future clinical studies and the development of risk-reduction strategies aimed at either assessing or modulating the risk of ONJ associated with BP.",
keywords = "Journal Article",
author = "Ppl Fung and G Bedogni and A Bedogni and Aviva Petrie and S Porter and G Campisi and J Bagan and V Fusco and G Saia and S Acham and Pellegrino Musto and Petrucci, {M T} and P Diz and G Colella and Mignogna, {M D} and M Pentenero and P Arduino and G Lodi and Carlo Maiorana and M Manfredi and P Hallberg and M Wadelius and K Takaoka and Leung, {Ying Ying} and R Bonacina and M Schi{\o}dt and P. Lakatos and Taylor, {S T} and {De Riu}, G and G Favini and Rogers, {S N} and M Pirmohamed and P Nicoletti and S Fedele and {GENVABO Consortium}",
note = "{\circledC} 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",
year = "2017",
month = "5",
doi = "10.1111/odi.12632",
language = "English",
volume = "23",
pages = "477--483",
journal = "Oral Diseases",
issn = "1354-523X",
publisher = "Wiley-Blackwell Munksgaard",
number = "4",

}

RIS

TY - JOUR

T1 - Time to onset of bisphosphonate-related osteonecrosis of the jaws

T2 - a multicentre retrospective cohort study

AU - Fung, Ppl

AU - Bedogni, G

AU - Bedogni, A

AU - Petrie, Aviva

AU - Porter, S

AU - Campisi, G

AU - Bagan, J

AU - Fusco, V

AU - Saia, G

AU - Acham, S

AU - Musto, Pellegrino

AU - Petrucci, M T

AU - Diz, P

AU - Colella, G

AU - Mignogna, M D

AU - Pentenero, M

AU - Arduino, P

AU - Lodi, G

AU - Maiorana, Carlo

AU - Manfredi, M

AU - Hallberg, P

AU - Wadelius, M

AU - Takaoka, K

AU - Leung, Ying Ying

AU - Bonacina, R

AU - Schiødt, M

AU - Lakatos, P.

AU - Taylor, S T

AU - De Riu, G

AU - Favini, G

AU - Rogers, S N

AU - Pirmohamed, M

AU - Nicoletti, P

AU - Fedele, S

AU - GENVABO Consortium

N1 - © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PY - 2017/5

Y1 - 2017/5

N2 - OBJECTIVES: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of bisphosphonates (BP). Although the risk of ONJ increases with increasing duration of BP treatment, there are currently no reliable estimates of the ONJ time to onset (TTO). The objective of this study was to estimate the TTO and associated risk factors in BP-treated patients.SUBJECTS AND METHODS: Retrospective analysis of data from 22 secondary care centres in seven countries relevant to 349 patients who developed BP-related ONJ between 2004 and 2012.RESULTS: The median (95%CI) TTO was 6.0 years in patients treated with alendronate (n = 88) and 2.2 years in those treated with zoledronate (n = 218). Multivariable Cox regression showed that dentoalveolar surgery was inversely associated, and the use of antiangiogenics directly associated, with the TTO in patients with cancer treated with zoledronate.CONCLUSIONS: The incidence of ONJ increases with the duration of BP therapy, with notable differences observed with respect to BP type and potency, route of administration and underlying disease. When data are stratified by BP type, a time of 6.0 and 2.2 years of oral alendronate and intravenous zoledronate therapy, respectively, is required for 50% of patients to develop ONJ. After stratification by disease, a time of 5.3 and 2.2 years of BP therapy is required for 50% of patients with osteoporosis and cancer, respectively, to develop ONJ. These findings have significant implications for the design of future clinical studies and the development of risk-reduction strategies aimed at either assessing or modulating the risk of ONJ associated with BP.

AB - OBJECTIVES: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of bisphosphonates (BP). Although the risk of ONJ increases with increasing duration of BP treatment, there are currently no reliable estimates of the ONJ time to onset (TTO). The objective of this study was to estimate the TTO and associated risk factors in BP-treated patients.SUBJECTS AND METHODS: Retrospective analysis of data from 22 secondary care centres in seven countries relevant to 349 patients who developed BP-related ONJ between 2004 and 2012.RESULTS: The median (95%CI) TTO was 6.0 years in patients treated with alendronate (n = 88) and 2.2 years in those treated with zoledronate (n = 218). Multivariable Cox regression showed that dentoalveolar surgery was inversely associated, and the use of antiangiogenics directly associated, with the TTO in patients with cancer treated with zoledronate.CONCLUSIONS: The incidence of ONJ increases with the duration of BP therapy, with notable differences observed with respect to BP type and potency, route of administration and underlying disease. When data are stratified by BP type, a time of 6.0 and 2.2 years of oral alendronate and intravenous zoledronate therapy, respectively, is required for 50% of patients to develop ONJ. After stratification by disease, a time of 5.3 and 2.2 years of BP therapy is required for 50% of patients with osteoporosis and cancer, respectively, to develop ONJ. These findings have significant implications for the design of future clinical studies and the development of risk-reduction strategies aimed at either assessing or modulating the risk of ONJ associated with BP.

KW - Journal Article

U2 - 10.1111/odi.12632

DO - 10.1111/odi.12632

M3 - Journal article

VL - 23

SP - 477

EP - 483

JO - Oral Diseases

JF - Oral Diseases

SN - 1354-523X

IS - 4

ER -

ID: 51573750